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ABSTRACT
Lysosomal acid lipase (LAL) is a critical neutral lipid metabolic enzyme that 
regulates metabolic reprogramming in myeloid-derived suppressor cells (MDSCs) 
through over-activation of mammalian target of rapamycin (mTOR). Affymetrix 
GeneChip microarray analysis of MDSCs from LAL deficient mouse (lal–/–) revealed 
upregulation of Rab7 GTPase protein, which belongs to a superfamily of small-
molecular-weight GTPase known to regulate intracellular membrane trafficking from 
early to late endosomes and lysosomes. Here, the physical protein-protein interaction 
between Rab7 GTPase and mTOR has been detected by co-immunoprecipitation in the 
cell extract of wild type HD1A and lal–/– MDSC-like HD1B myeloid cell lines. The GST pull 
down assay using the recombinant GST-Rab7 GTPase fusion protein showed that Rab7 
GTPase interacts with the mTOR N-terminal heat repeat domain. Rab7 GTPase siRNA 
knocking down reversed the altered lysosome/mTOR distribution and expression 
levels in HD1B cells. Rab7 GTPase siRNA knocking down in isolated bone marrow lal–/– 
MDSCs or HD1B cells not only reduced over-activation of mTOR and its downstream 
effector S6, but also decreased glucose consumption, decreased ROS over-production, 
and increased healthy mitochondria by membrane potential measurement. Inhibition 
of Rab7 GTPase led to reduced lal–/– MDSCs differentiation from bone marrow Lin– 
progenitor cells, reduced lal–/– MDSCs trans-endothelial migration, and reversed lal–/– 
MDSCs suppression of T cell proliferation. Furthermore, inhibition of Rab7 GTPase 
reduced lal–/– MDSCs ability to stimulate tumor cell proliferation in vitro, tumor growth 
in vivo, and tumor invasion. Together, these results showed that Rab7 GTPase is 
critically involved in MDSCs homeostasis and pathogenic functions. 
INTRODUCTION
Sporadic tumor cells arise from various genetic 
or epigenetic defects. The immune surveillance system 
in the body detects and destroys newly formed tumor 
cells, and prevents them from growing and spreading. 
When immune surveillance is compromised, unchecked 
tumor cells proliferate and grow freely to form tumor [1]. 
Inflammatory responses play decisive roles at different 
stages of tumor development, including initiation, 
promotion, malignant conversion, invasion, and metastasis 
[2, 3]. One of manifestations of inflammation is the 
expansion of myeloid-derived suppressor cells (MDSCs) 
which are commonly defined by the markers CD11b 
(integrin α-M) and Gr-1 (Ly6-C/G) in mouse [4]. The 
hallmark of MDSCs is their ability to suppress immune 
surveillance (T cells, NK cells etc). Recently, we have 
made a major breakthrough and identified that MDSCs are 
able to directly stimulate tumor cell proliferation in vitro, 
and tumor growth and invasion in vivo [5–8]. 
As a control center of signaling for metabolic 
reprogramming, lysosome plays a vital role in various 
cellular functions [9]. We have shown that lipid metablic 
signaling controlled by lysosomal acid lipase (LAL) 
in lysosome plays a critical role in malformation and 
malfunction of MDSCs [3]. Fatty acids supply energy, as 
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mitochondrial fatty acid oxidation produces more than twice 
as much ATP per mole as oxidation of glucose or amino 
acids. In the absence of LAL that hydrolyzes cholesteryl 
esters and triglycerides to generate free cholesterol and free 
fatty acids in the lysosomes, LAL deficient (lal–/–) MDSCs 
have to use alternative metabolic pathways to compensate 
the energy deficit, which leads to increased glycolytic 
metabolism, increased ATP production, ROS over-
production, and impairment of mitochondrial membrane 
potential as a result of mammalian target of rapamycin 
(mTOR) over-activation [7, 10]. Ingenuity Pathway 
Analysis of Affymetrix GeneChip microarray revealed 
up-regulation of multiple genes in the mTOR signaling 
pathway [10]. mTOR serves as a nutrient/energy/redox 
sensor for cell growth and belongs to the phosphoinositide 
3-kinase (PI3K)-related protein kinases (PIKK) family 
[11–13].  In an array of studies recently conducted in our 
laboratories, we have clearly demonstrated that mTOR 
critically regulates multi-aspects of lal–/– MDSCs, including 
development, systemic expansion, trans-endothelial 
migration, immune suppression, and direct stimulation of 
tumor cell proliferation [3, 5–7, 14, 15]. 
Evidence suggests that membrane trafficking 
causes mTOR to shuttle to lysosomes and regulate 
mTOR signaling [16, 17]. The lysosomal membrane acts 
as a platform for the mTOR signaling. Since LAL is a 
lysosomal enzyme, lacking the LAL activity influences 
endomembrane trafficking and changes the mTOR 
activity. In searching for lysosomal proteins that might 
control mTOR trafficking and activity, Rab7 GTPases was 
up-regulated in lal–/– MDSCs [10]. Through the interaction 
with its partners, Rab7 GTPase participates in multiple 
regulatory mechanisms in endosomal sorting, biogenesis 
of lysosome and phagocytosis [18].  Recently, the specific 
role of Rab7 GTPase in cancer cell proliferation and 
invasion begins to unravel. In the literature, Rab7 GTPase 
is pro-tumorigenic in both aspects [19–21]. However, 
its role in tumor-promoting MDSCs has never been 
explored. Here, we identified that Rab7 GTPase regulates 
the mTOR activity through a direct physical interaction 
in normal myeloid cells and lal–/– MDSCs. Inhibition of 
Rab7 GTPase over-activation reduced various pathogenic 
functions of lal–/– MDSCs. 
RESULTS
Rab7 GTPase interacts with the mTOR complex 
to influence its downstream signaling
Since both over-activation of the mTOR signaling 
pathway and increased Rab7 GTPase expression co-
exist in lal–/– MDSCs [10], we hypothesized that the 
mTOR signaling pathway is regulated by Rab7 GTPase. 
The Rab7 GTPase was blocked by siRNA transfection 
in  MDSCs-like HD1B cells (lal–/–) and control 
wild type HD1A cells [7]. As shown in Figure 1A, HD1B 
cells had higher expression levels of Lysosomal associate 
membrane protein 1 LAMP1 and mTOR, but not S6. 
The Rab7 GTPase siRNA knocking down effectively 
reduced the Rab7 GTPase protein level in both HD1A 
and HD1B cells. Interestingly, Rab7 GTPase knocking 
down reduced expression of LAMP1 in both HD1A and 
HD1B cells. Rab7 GTPase knocking down also reduced 
mTOR, pmTOR, and pS6 levels in HD1B cells. These 
results showed that Rab7 GTPase is critical for activation 
of mTOR signaling and lysosome genesis. 
Based on these observations, immunoprecipitation 
was performed. As shown in Figure 1B, the intensity of 
mTOR protein was much stronger in the cell lysate of HD1B 
cells than that of HD1A cells after immunoprecipitation by 
anti-Rab7 GTPase antibody. To further confirm this finding, 
a GST pulldown study was performed using purified 
recombinant proteins (Figure 1C, left). After incubation 
with cell extracts of HD1A and HD1B cells, the GST-Rab7 
GTPase fusion protein pulled down the intracellular mTOR 
complex in both HD1A and HD1B cells (Figure 1C, right), 
with much stronger intensity of mTOR in HD1B cells than 
that in HD1A cells. As a control, GST pulldown showed a 
very weak non-specific band in both cell lines. Therefore, 
Rab7 GTPase is physically associated with mTOR and 
LAL deficiency leads to the enhanced interaction between 
these two proteins in myeloid cells.
Define the mTOR domains interacting with 
Rab7 GTPase
The mTOR is a very large protein (2516 aa) and 
contains multiple functional domains (Figure 2A). While it 
was too difficult to amplify the full length of mTOR, various 
mTOR fragments were amplified by PCR and subcloned 
into the pGEX-4T-1 vector (Figure 2A, M1A, M1B, M2a2, 
M2b, and M3, and M4) to cover the entire mTOR region, 
and expressed as GST-fusion proteins (Figure 2C). Rab7 
GTPase was generated by thrombin cleavage of bacterial 
expressed GST-Rab7 GTPase fusion protein and used for 
pulldown assay (Figure 2B). GST was used as a baseline 
control. As demonstrated in Figure 2D, mTOR fragments of 
GST-M1A, GST-M1B, GST-M2A2, GST-M2b were able to 
pull down the recombinant Rab7 GTPase protein, whereas 
GST-M3 and GST-M4 were not. The same observation 
was confirmed by GST pulldown of endogenous Rab7 in 
HD1A and HD1B cell extracts by the recombinant GST-
mTOR fragments (Figure 2E). These results indicate that 
Rab7 GTPase directly interacts with mTOR through the 
N-terminal heat repeat domain of mTOR. 
Rab7 GTPase controls lysosome cellular distri-
bution in LAL deficient cells
As demonstrated in Figure 3A, LAL deficient HD1B 
cells significantly induced lysosomal genesis and showed 
much more LysoTracker positive lysosomes around the 
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perinuclear region than those in wild type HD1A cells. 
Knocking down Rab7 GTPase by siRNA reduced lysosomal 
genesis and re-located lysosomes by immunofluorescence 
co-staining of lysosomal marker LAMP1 and Rab7 
GTPase, in which Rab7 GTPase was co-localized with 
LAMP1 on the lysosomes (Figure 3B and Supplementary 
Figure 1A). Figure 3B and Supplementary Figure 1A also 
showed that Rab7 GTPase siRNA effectively knocked 
down Rab7 GTPase expression in both HD1A and HD1B 
cells. Similarly, mTOR and LAMP1 were co-localized 
in HD1B cells and only partially overlapped in HD1A 
cells (Supplementary Figure 1B). The image confirmed 
Figure 1: Rab7 GTPase and mTOR interaction. (A) Knocking down Rab7 GTPase by siRNA reduced LAMP1, mTOR, 
phosphorylated mTOR and phosphorylated S6 protein levels in HD1B cells. HD1A and HD1B cells were transfected with or without 
control or Rab7 GTPase siRNA for 3 d, and cell lysates were subjected to Western blot analysis; (B) Immuno-precipitation assay of Rab7 
GTPase and mTOR interaction. HD1A and HD1B cell lysates were immuno-precipitated by control IgG (IgG) or anti-Rab7 GTPase 
antibody (Rab7), and detected by anti-mTOR antibody in Western blot analysis; (C) GST pulldown assay of Rab7 GTPase and mTOR 
interaction. Left panel, GST and GST-Rab7 fusion protein were expressed in E.coli and purified by GST column. The purity of recombinant 
proteins were visualized by coomassie blue staining on SDS-PAGE. Right panel, HD1A and HD1B cell lysates were incubated with 
purified recombinant GST or GST-Rab7 fusion protein and pull down with GST-beads, and detected by anti-mTOR antibody in Western 
blot analysis. For A-C, representative results are shown from three independent experiments.
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Figure 2: GST pulldown of Rab7 GTPase with mTOR domains. (A) The schematic diagram of the mTOR domain structure 
(Upper), and PCR-generated GST-mTOR fusion fragments (Lower); (B) GST cleavage of GST-Rab7 fusion protein by thrombin 
and analyzed by coomassie blue staining (Left), and confirmed by Western blot analysis using anti-Rab 7 GTPase antibody (Right); 
(C) Expression and purification of various recombinant GST-mTOR fragments; (D) Pull-down of recombinant Rab7 GTPase by recombinant 
GST-mTOR fragments; (E) Pull-down of endogenous Rab7 GTPase in HD1A or HD1B cells by recombinant GST-mTOR fragments. From 
B-E, results are representative of three independent experiments.
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that knocking down Rab7 GTPase reduced lysosomal 
genesis and re-located lysosomes as evidenced by mTOR 
and LAMP1 co-localization in HD1B cells (Figure 3C, 
Supplementary Figure 1B). Since Rab7 GTPase and mTOR 
are physically interactive, it is important to determine if 
they are co-localized in HD1A and HD1B cells. In both 
HD1A and HD1B cells Rab7 GTPase and mTOR were 
co-localized in a large extent (Figure 3D, Supplementary 
Figure 1C). Knocking down Rab7 GTPase reduced 
mTOR signals in both cells (Figure 3D). Therefore, LAL 
deficiency-induced Rab7 GTPase upregulation is critically 
involved in lysosomal genesis and distribution in myeloid 
cells through interacting with the mTOR pathway.
Rab7 GTPase regulates glucose metabolic switch 
in myeloid cells
As a result of metabolic reprogramming of LAL 
deficiency and mTOR over-activation, HD1B cells have an 
increased intracellular glucose level, increased expression 
of glucose transporter genes and enzymes that are critical 
for glucose metabolism [7]. As shown in Figure 4A, LAL 
deficient HD1B cells have a much higher level of the 
intracellular glucose level than that of wild type HD1A 
cells. Knocking down Rab7 GTPase significantly reduced 
the glucose level in HD1B cells. Among four glucose 
transporter genes (GluT3, Glut5, Glut6 and Glut13) that 
were changed expression in HD1B cells vs HD1A cells, 
expression of Glut6 and Glut13 was selectively reduced by 
Rab7 GTPase knocking down (Figure 4B). This steady-state 
of mRNA levels could be due to either decreased expression 
or increased degradation or both. The increased expression 
of HK1 in HD1B cells was reduced by Rab7 GTPase 
knocking down while the increased expression of IDH1 in 
HD1B cells was not (Figure 4B). This concludes that Rab7 
GTPase controls the glucose consumption switch in lal–/– 
MDSCs and partially overlaps with mTOR over-activation. 
Rab7 GTPase controls ROS production and 
mitochondrial membrane potential
Increased glycolysis and over-activation of the 
mTOR signaling pathway in LAL deficient myeloid 
cells resulted in the increased ROS production and 
mitochondrial membrane potential alteration [7, 14]. 
Transfection of Rab7 GTPase siRNA effectively blocked 
the Rab7 GTPase expression level compared to that 
of control siRNA in bone marrow lal–/– Ly6G+ cells 
(Figure 5A). Knocking down Rab7 GTPase by siRNA 
significantly reduced the ROS production in lal–/– Ly6G+ 
cells. This result was further confirmed in MDSCs-like 
HD1B cells (Figure 5B). The damaged mitochondrial 
membrane potential was a major contributing factor 
of ROS over-production. There were more healthy 
mitochondria (JC-1 red staining cells) in wild type Ly6G+ 
cells and HD1A cells than those in lal–/– Ly6G+ and HD1B 
cells (Figure 5C–5D). Rab7 GTPase siRNA knocking 
down partially reversed damaged mitochondria (JC-1 
green staining cells) to healthy mitochondria in Ly6G+ 
cells and HD1B cells (Figure 5C–5D). 
Rab7 GTPase controls MDSCs differentiation, 
trans-EC migration and T cell suppression
LAL deficiency results in increased differentiation 
of MDSCs from lineage negative (Lin-) bone marrow cells 
[22], which is mTOR signaling pathway dependent [14]. To 
see if Rab7 GTPase participates in MDSCs differentiation, 
Lin- cells were transfected with control or Rab7 
GTPase siRNA. Knocking down Rab7 GTPase reduced 
CD11b+Ly6G+ cell differentiation from lal–/– Lin- cells 
(Figure 6A). lal–/– Ly6G+ cells have much stronger trans-
endothelial ability than that of wild type Ly6G+ cells, which 
is mediated by mTOR over-activation [15]. Rab7 GTPase 
siRNA knocking down reduced bone marrow derived lal–/– 
Ly6G+ cells’ trans-endothelial migration (Figure 6B). In 
organs, lal–/– MDSCs exhibit very strong suppression on 
T cells through over-activation of mTOR [14]. Knocking 
down Rab7 GTPase in bone marrow or bronchoalveolar 
lavage fluid (BALF) derived lal–/– Ly6G+ cells reduced their 
suppression of T cell proliferation (Figure 6C).
Rab7 GTPase controls MDSCs stimulation of 
tumor cell proliferation, growth and invasion
We are the first group showing that MDSCs directly 
stimulate proliferation of various tumor cells in vitro, 
tumor growth in vivo and metastatic invasion, which are 
mediated by over-activation of mTOR [6]. Rab7 GTPase 
siRNA transfected bone marrow Ly6G+ cells were co-
cultured with B16 melanoma cells or LLC cells in vitro. 
Both B16 melanoma cells and LLC cells had significantly 
increased cell numbers when co-cultured with lal–/– Ly6G+ 
cells than those with wild type Ly6G+ cells. Knocking 
down Rab7 GTPase reduced ability of lal–/– Ly6G+ cells 
to stimulate tumor cell proliferation in vitro (Figure 7A).
Ly6G+ cells from C57BL/6 or FVB/N mice 
were transfected with control or Rab7 GTPase siRNA, 
and mixed with B16 melanoma cells or LLC cells for 
subcutaneous injection in the flank sites of corresponding 
wild type C57BL/6 or FVB/N recipient mice. At 10 days 
post injection, the sizes of B16 and LLC tumors grew 
bigger when co-injected with the lal–/– Ly6G+ cells than 
those with the wild type Ly6G+ cells in both syngeneic 
C57BL/6 recipient mice (Figure 7B) and allogeneic 
FVB/N recipient mice (Figure 7C). In both syngeneic and 
allogenic recipient mice, knocking down Rab7 GTPase by 
siRNA in wild type Ly6G+ cells did not show significant 
changes in tumor growth. Knocking down Rab7 GTPase 
in lal–/– Ly6G+ cells significantly reduced their tumor 
growth-stimulating ability in syngeneic C57BL/6 mice 
for both B16 melanoma and LLC tumor (Figure 7B). In 
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Figure 3: Rab7 GTPase controls lysosome genesis. (A) LysoTracker Red staining of HD1A or HD1B cells with control or Rab7 
GTPase siRNA treatment for 3 d. Lysosomal perinuclear location was intensified in HD1B cells. Top, A longer exposure of HD1A cell; 
scale bar, 20 µm. (B) Co-localization of Rab7 GTPase and LAMP1 by immunofluorescent staining in HD1A and HD1B cells with control 
or Rab7 GTPase siRNA transfection for 3 d; (C) Co-localization of mTOR and LAMP1 by immunofluorescent staining in HD1A and HD1B 
cells with control or Rab7 GTPase siRNA transfection for 3 d. Notice the mTOR staining intensity was reduced by Rab7 GTPase siRNA 
knocking down; (D) Co-localization of Rab7 GTPase and mTOR by immunofluorescent staining in HD1A and HD1B cells with control or 
Rab7 GTPase siRNA transfection for 3 d. The mTOR staining intensity was reduced by Rab7 GTPase siRNA knocking down. From A–D, 
results are representative of five independent experiments. B-D, scale bar, 10 µm. -, no transfection; C, transfected with control siRNA; 
Rab7, transfected with Rab7 siRNA. 
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allogeneic FVB/N recipient mice, only LLC tumor growth 
was affected whereas B16 melanoma had no statistical 
difference (Figure 7C). 
Likewise, knocking down Rab7 GTPase of wild 
type Ly6G+ cells did not show significant changes in tumor 
invasion of B16 melanoma, but knocking down Rab7 
GTPase of lal–/– Ly6G+ cells significantly reduced invasion 
of B16 melanoma (Figure 7D). A similar observation has 
been made in the LLC tumor model, in which LLC cell 
co-injection with lal–/– Ly6G+ cells transfected with control 
siRNA showed tumor cell invasion in the lung (more Ki67 
positive staining), whereas knocking down Rab7 GTPase 
abolished LLC cell invasion in the lung (Figure 7E 
and 7F). No LLC invasion was observed when LLC cells 
were co-injected with wild type Ly6G+ cells regardless of 
control or Rab7 GTPase siRNA transfection.
DISCUSSION
Fatty acids and glucose are two main sources 
for fueling energy generation in mitochondria through 
two oxidation processes, β-oxidation and oxidative 
phosphorylation (OXPHOS).  They generate acetyl-CoA 
to enter the Kreb cycle and make ATP through passing 
the respiratory chain and building proton potential on 
the mitochondrial membrane. The deficiency in LAL 
leads to fatty acid paucity and blocks ATP generation 
through β-oxidation in myeloid lineage cells. As a 
result, myeloid cells undergo a major metabolic shift to 
overuse the glycolytic pathway in order to compensate 
energy deficit. Overuse of the glycolytic pathway 
caused impaired mitochondrial function and increased 
expression of respiratory chain proteins (including 
Figure 4: Rab7 GTPase controls glucose metabolism in myeloid cells. (A) The glucose level was measured in HD1A and 
HD1B cells with control or Rab7 GTPase siRNA transfection; (B) Real time PCR analyses of Glut3, Glut5, Glut6, Glut13, HK1, and IDH1 
expression in HD1A and HD1B cells with control or Rab7 GTPase siRNA transfection. The housekeeping gene β-Actin was used as internal 
control. In all above, results are mean ± SD, n = 3–4, *p < 0.05. **p < 0.001. -, no transfection; C, transfected with control siRNA; Rab7, 
transfected with Rab7 siRNA. 
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NADH dehydrogenases, cytochrome proteins, ATPases 
and mitochondrial ribosomal proteins) with penalties: 
leading to oxidative stress and increased ROS production 
in lal–/– MDSCs [7, 10, 14]. High levels of ROS allow for 
the stimulation of cell proliferation, induction of genetic 
instability, and evasion from senescence [23]. 
As we reported previously, the mTOR complexes 
coordinate metabolic reprogramming in MDSCs [7, 10, 14]. 
Membrane trafficking causes mTOR to shuttle to 
lysosomes and regulate mTOR signaling [16, 17]. 
Therefore, identification of factors that regulate the mTOR 
trafficking in cells will greatly facilitate understanding of 
Figure 5: Rab7 GTPase controls ROS production and the mitochondrial membrane potential. (A) Western blot analysis of 
Rab7 GTPase expression in wild type and lal–/– bone marrow Ly6G+ cells with control or Rab7 GTPase siRNA transfection for 2 d. Actin 
was used as loading control. Results are representative of three independent experiments; (B) ROS production in wild type and lal–/– bone 
marrow Ly6G+ cells, or in HD1A and HD1B myeloid cells with control or Rab7 GTPase siRNA transfection. ROS levels were measured by 
flow cytometry. Results are mean ± SD, n = 4, *p < 0.05, **p < 0.001; (C) The mitochondrial membrane potential in wild type and lal–/– 
bone marrow Ly6G+ cells, with control or Rab7 GTPase siRNA transfection. The mitochondrial membrane potential was measured using 
JC1 staining by flow cytometry. The results are mean from four independent experiments (n = 4), *p < 0.05, **p < 0.001; For A-C, -, no 
transfection; C, transfected with control siRNA; Rab7, transfected with Rab7 siRNA. (D) The mitochondrial membrane potential of HD1A 
and HD1B cells was measured by fluorescence microscope. Results are representative of three independent experiments, scale bar, 25 µm. 
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MDSCs homeostasis and functions. Affymetrix GeneChip 
microarray analysis of bone marrow lal–/– MDSCs has 
identified several Rab GTPases that were up-regulated 
[10]. Among them, Rab7 GTPase is more appealing. It 
has been well documented that Rab7 GTPase is a late 
endosome-/lysosome-associated small GTPase, perhaps 
the only lysosome-associated Rab GTPase protein 
identified to date [24–27]. Rab7 GTPase participates in 
multiple regulatory mechanisms in endosomal sorting, 
biogenesis of lysosome and phagocytosis. These processes 
Figure 6: Rab7 GTPase controls MDSCs differentiation and T cell suppression. (A) Wild type or lal–/– Lin- cells were isolated 
from 3-month old mice, and transfected with control or Rab7 GTPase siRNA for 5 d. Differentiated CD11b+Ly6G+ cells were measured 
by flow cytometry; (B) Transendothelial migration of wild type or lal–/– bone marrow Ly6G+ cells that were transfected with control or 
Rab7 GTPase siRNA; (C) T cell suppression of wild type or lal–/– Ly6G+ cells that were transfected with control or Rab7 GTPase siRNA 
by flow cytometry. lal–/– Ly6G+ cells were isolated from the bone marrow or BALF. Representative T cell in vitro proliferation profiles are 
shown on the left and the statistical analyses are shown on the right. In all above, results are mean ± SD, n = 4, *p < 0.05. **p < 0.001. -, 
no transfection; C, transfected with control siRNA; Rab7, transfected with Rab7 siRNA. 
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Figure 7: Rab7 GTPase controls tumor stimulation of lal–/– MDSCs. (A) Ly6G+ cells from the wild type or lal–/– bone marrow 
were transfected with control or Rab7 GTPase siRNA for 24 h, and 2 × 105 transfected Ly6G+ cells were co-cultured with B16 melanoma 
cells (2 × 104) or LLC cells (2 × 104) in vitro. Cells were counted 48 h later. Data were expressed as mean ± SD, n = 5. *P < 0.05, 
**P < 0.001; -, no transfection; C, transfected with control siRNA; Rab7, transfected with Rab7 siRNA. (B) Ly6G+ cells from the syngeneic 
C57BL/6 wild type or lal–/– bone marrow were transfected with control or Rab7 GTPase siRNA for 24 h. Transfected Ly6G+ cells were 
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are closely related to substrates degradation, antigen 
presentation, cell signaling, cell survival, microbial 
pathogen infection, and movement of secretory granules 
[28, 29]. Consistently, mutations or dysfunctions of Rab7 
GTPase result in traffic disorders, which cause various 
diseases, such as cancer, lipid metabolism disease and 
neuropathy [18, 25, 30]. More evidence has unraveled that 
Rab7 small GTPase is involved in cancer formation [19–
21] . Rab7 small GTPase is an early-induced melanoma 
driver whose levels can be upregulated in melanoma 
as part of a lysosomal-associated signature [19]. It has 
been demonstrated that troglitazone prevents invasion in 
prostate cancer cell after extracellular acid pH stimuli, 
in which Rab7 regulates cell surface-directed lysosome 
trafficking [31]. Troglitazone is a peroxisome proliferator-
activated receptor-γ (PPAR-γ) agonist [32]. LAL 
downstream derivatives serve as ligands for PPAR-γ [3]. 
In cancer-stimulating MDSCs, we have recently shown 
that activation of PPARγ by ligand treatment inhibited lal–
/– MDSCs stimulation of tumor cell growth and invasion 
in vivo, and tumor cell proliferation and migration 
in vitro through correction of lal–/– MDSCs transendothelial 
migration, and differentiation from bone marrow Lin- 
cells. The corrective effects of the PPARγ ligand on 
lal–/– MDSCs functions were mediated by regulating the 
mTOR pathway, and subsequently blocking MDSCs ROS 
overproduction [5]. 
Here, Rab7 GTPase knocking down resulted in 
reduced expression of LAMP1 in MDSCs-like HD1B cells 
along with down regulation of the mTOR downstream 
signaling (Figure 1A), indicating that lysosomal anchored 
Rab7 GTPase controls lysosome genesis by regulating the 
mTOR signaling. LAL deficient HD1B cells increased 
lysosomal genesis more around the perinuclear region 
(Figure 3A–3C). Importantly, the protein-protein physical 
interaction has been detected for the first time between 
Rab7 GTPase and mTOR subunit in both HD1A and 
HD1B cell extract and the purified fusion protein system 
(Figure 1B–1C and Figure 2). It appeared that Rab7 
GTPase interacted with the mTOR through its N-terminal 
heat repeat domain (Figure 2D and 2E). This was further 
supported by co-localization of Rab7 GTPase and mTOR 
on lysosomes (Lamp1 staining) in HD1A and HD1B cells 
(Figure 3D). Rab7 GTPase knockdown reduced lysosomal 
genesis and relocated lysosomes from the perinuclear 
area to spread in cytosol of HD1B cells (Figure 3A–3C). 
Therefore, LAL-controlled Rab7 GTPase is a critical 
component in modulation of lysosomal genesis and 
cellular trafficking in myeloid cells.
At the cellular level, we have reported that over-
activation of mTOR, the master metabolic regulator, 
leads to an increased intracellular glucose consumption 
and increased gene expression of glucose transporters 
(Gluts) and enzymes that are critically involved in the 
glycolytic pathway in HD1B cells [7]. This gave us a 
reason to speculate that mTOR-associated Rab7 GTPase 
on lysosome may attribute to this metabolic transition. 
Indeed, knocking down Rab7 GTPase significantly 
reduced the glucose consumption level and gene 
expression of glucose transporters (Glut6 and Glut13) and 
HK1 in HD1B cells (Figure 4A–4B).  As a consequence, 
the increased glycolysis and over-activation of mTOR 
resulted in the increased ROS production, which was 
decreased by blocking Rab7 GTPase (Figure 5B) in lal–/– 
MDSCs and MDSCs-like HD1B cells. Furthermore, the 
damaged mitochondrial membrane potential, a major 
contributing factor for ROS overproduction, was reversed 
in lal–/– MDSCs and HD1B cells by knocking down Rab7 
GTPase (Figure 5C). These results indicate that Rab7 
GTPase not only physically interacts with the mTOR 
complex, but also influences mTOR cellular functions in 
myeloid cells. 
One manifestation of LAL deficiency in lal–/– mice 
is systemic expansion of tumor-promoting MDSCs. 
This pathogenic phenotype is mainly contributed by 
two factors that are controlled by mTOR as we reported 
before. First, increased myelopoiesis is the major cause 
for MDSCs expansion in lal–/– mice [22]. Bone marrow 
lal–/– Lin- progenitor cells accelerated into differentiation 
of lal–/– MDSCs as a result of mTOR over-activation [14]. 
Inhibition of mTOR-associated Rab7 GTPase reduced 
MDSCs differentiation from bone marrow lal–/– Lin- 
cells (Figure 6A). Second, lal–/– MDSCs possess a strong 
ability to penetrate the endothelial membrane under the 
control of mTOR [15]. Rab7 GTPase inhibition reduced 
lal–/– MDSCs trans-endothelial migration significantly 
mixed with B16 melanoma cells (2 × 105) or LLC cells (5 × 105) (3:1), followed by subcutaneously flank injection into C57BL/6 wild type 
recipient mice. Tumor sizes were measured at post injection day 10. The average tumor size of each group and p values are marked with 
n = 10; (C) Ly6G+ cells from the allogeneic FVB/N wild type or lal–/– bone marrow were transfected with control or Rab7 GTPase siRNA 
for 24 h. Transfected Ly6G+ cells were mixed with B16 melanoma cells (2 × 105) or LLC cells (5 × 105) (3:1), followed by subcutaneously 
flank injection into the FVB/N wild type recipient mice. Tumor sizes were measured at post injection day 10. The average tumor size of 
each group and p values are marked with n = 12; (D) Ly6G+ cells from C57BL/6 wild type or lal–/– bone marrow were transfected with 
control or Rab7 GTPase siRNA for 24 h. Transfected Ly6G+ cells (2.5 × 106) were mixed with B16 melanoma cells (5 × 105) (5:1), followed 
by intravenously injection into C57BL/6 wild type recipient mice through tail vein. B16 melanoma colony numbers were counted at 
2 weeks post injection. The average colony number of each group and p values are marked with n = 10; (E) Ly6G+ cells from C57BL/6 wild 
type or lal–/– bone marrow were transfected with control or Rab7 GTPase siRNA for 24 h. Transfected Ly6G+ cells (2.5 × 106) were mixed 
with LLC cells (5 × 105) (5:1), and intravenously injected into C57BL/6 wild type recipient mice through tail vein. Lung histology of LLC 
invasion was examined at 2 months post injection. The representative H & E sections were shown, n = 10 mice; (F) Ki67 staining of E. For 
A-F: -, no transfection; C, transfected with control siRNA; Rab7, transfected with Rab7 siRNA. 
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(Figure 6B). Upon exiting the bone marrow and infiltration 
into distal organs (e.g. lung), the hallmark pathogenic 
feature of lal–/– MDSCs is to suppress anti-tumor immunity 
by down regulating T cell proliferation. This suppressive 
activity was decreased by Rab7 GTPase knockdown 
in either bone marrow or BALF derived lal–/– MDSCs 
(Figure 6C). 
Anti-tumor immunity is an indirect effect by 
MDSCs to eradicate tumor initiation, progression and 
invasion in lal–/– mice, which often takes a longer time to 
respond. Given the fact that lal–/– MDSCs and tumor cells 
are often coexist and traveling together in the body, direct 
stimulation of tumor cells by lal–/– MDSCs as we showed 
recently [6] is a quick and more profound effect on tumor 
growth and spreading. This direct tumor stimulating effect 
of lal–/– MDSCs is also controlled by mTOR. In co-culture 
and co-injection of lal–/– MDSCs with tumor cells, Rab7 
GTPase knockdown of lal–/– MDSCs reduced proliferation 
of B16 melanoma cells and LLC cells in vitro (Figure 7A), 
tumor growth in both syngeneic and allogeneic recipient 
mice (Figure 7B–7C), and invasion (Figure 7D–7F), 
suggesting that Rab7 GTPase is critically involved in the 
LAL/mTOR axis to control tumorigenesis.
In summary, Rab7 GTPase plays a key role in 
regulating MDSCs development, differentiation, trans-
endothelial migration, anti-tumor immunity and direct 
tumor stimulation through physical interaction with the 
mTOR complexes. Trafficking regulation of lysosomal 
anchored proteins in MDSCs such as mTOR and Rab 
GTPases provides a new direction for immunotherapy in 
cancer treatment.
MATERIALS AND METHODS
Animal care
All scientific protocols involving the use of animals 
in this study have been approved by the Institution 
Animal Care and Usage Committee (IACUC) of Indiana 
University School of Medicine (Indianapolis, IN) 
and followed the guidelines established by the Panel 
on Euthanasia of the American Veterinary Medical 
Association. Protocols involving the use of recombinant 
DNA or biohazard materials have been approved by 
the Institutional Biosafety Committee and followed the 
guidelines established by the National Institutes of Health. 
Animals were housed under IACUC-approved conditions 
in a secured animal facility at Indiana University School 
of Medicine and were regularly screened for common 
pathogens. Experiments involving animal sacrifice used 
an approved euthanasia protocol.
Western blot analysis 
Western blot analysis of HD1A and HD1B cells was 
performed following our previous procedure [7, 8]. 
Purification of recombinant Rab7 GTPase and 
mTOR truncated fusion proteins
Total mRNAs were isolated from HD1B cells 
and reverse transcribed into cDNAs. The full-length 
mouse Rab7 GTPase coding region and mTOR fragment 
coding regions were amplified by PCR from cDNAs 
and subcloned into the pGEX-4T-1 vector (GE life 
science, Pittsburgh, PA), which was confirmed by DNA 
sequencing. Rab7 GTPase-GST fusion protein was 
expressed in BL21 E. coli by 100 μM IPTG induction 
and purified by Glutathione Sepharose 4 Fast Flow (GE 
life science). GST was removed from GST-Rab7 GTPase 
fusion protein by thrombin cleavage. To get the soluble 
fusion protein, the inclusion bodies were dissolved in 6M 
urea and slowly renatured by adding 10 volume buffer 
(25 mM Tris pH7.5). Centricon (Millipore, Billerica MA) 
was used to remove additional urea, and the final urea 
concentration was below 0.6 mM.
Immuno-precipitation assay
Rabbit IgG or rabbit anti-Rab7 GTPase antibody 
(9367S, Cell signaling, Beverly, MA) was incubated with 
200 μl cell lysate of HD1A or HD1B cells (equivalent to 
1–2 × 106 cell) at 4°C for 2 h. Protein A agarose (50% bead 
slurry, 20 µl) was added and incubated for 1 h at 4°C and 
washed with cell lysis buffer (Cell signaling) 4 times. The 
beads were boiled in SDS sample buffer before loaded on 
SDS-PAGE. Proteins associated with the Rab7 GTPase 
protein were detected by Western blotting analysis using 
anti-mTOR antibody (2983S, Cell signaling, Beverly, MA). 
Pulldown assay
Glutathione-agarose beads (50% slurry, 40 μl) were 
incubated with 100 pmole of GST (2.7 μg), or GST-Rab7 
GTPase (5.1 μg) in 160 μl wash buffer (50 mM Tris, 
150 mM NaCl, pH8.0) in a 0.5 ml micro tube at room 
temperature for 30 minutes, and washed with buffer for 
3 times. The beads were incubated with 200 μl cell lysate 
of HD1A or HD1B cells (equivalent to 1–2 × 106 cells) at 
4°C for 2 h and washed four times with 500 μl of wash 
buffer. The beads were boiled in SDS sample buffer before 
loading on SDS-PAGE. 
To evaluate the interaction between Rab7 GTPase 
and mTOR truncated fragments, glutathione-agarose beads 
(50% slurry, 40 μl) were incubated with 100 pmole of 
GST (2.7 μg), GST-mTOR-1A (7.3 μg), GST-mTOR-1B 
(7.04 μg), GST-mTOR-M2a2 (5.7 μg), GST-mTOR-M2b 
(4.8 μg), GST-mTOR-M3 (12.6 μg), or GST-mTOR-M4 
(7.4 μg) in 160 μl wash buffer (50 mM Tris, 150 mM 
NaCl, pH8.0) in 0.5 ml micro tube at room temperature 
for 30 minutes, and washed with wash buffer for 
3 times. The beads were incubated with 200 μl cell lysate 
of HD1A or HD1B cells (equivalent to 1 – 2 × 106 cells) 
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at 4 oC for 2 h and washed four times with 500 μl of wash 
buffer. The beads were boiled in SDS sample buffer before 
loading on SDS-PAGE. Proteins associated with the 
mTOR truncated fragment fusion protein were detected 
by Western blotting using anti-Rab7 GTPase antibody. 
Pulldown of recombinant Rab7 GTPase (after GST 
removal) by various GST-mTOR fragment fusion proteins 
was performed similarly.
Glucose measurement 
The concentration of glucose in HD1A or HD1B 
cells was measured by glucose assay kit (Sigma) according 
the manufacturer’s instruction [7]. 
Real time PCR
Total RNAs from HD1A or HD1B cells were 
purified using the Qiagen total RNA purification kit 
(Qiagen, Valencia, CA). cDNAs were generated by 
SurperScriptTM III (Invitrogen). Real-time PCR for Glut1-
Glut13, HK1-HK3, IDH1 and the house keeping gene 
β-Actin were performed on a StepOnePlusReal-Time 
PCR System (Applied Biosystems) using Power SYBR® 
Green PCR Master Mix (Applied Biosystems). The 
(2–ΔΔCt) algorithm was used to determine the relative gene 
expression level [7]. 
Rab7 GTPase siRNA sequences
Three sets of Rab7 siRNAs were designed and 
synthesized by Integrated DNA Technologies using 
Custom Dicer-Substrate siRNA software.
Rab7 siRNA1: 
Sense, 5′  rArCrArGrGrArArArCrArGrArArGrUr 
GrGrArArCrUrGrUAC 
Antisense, 5′  rGrUrArCrArGrUrUrCrCrArCrUrUr 
CrUrGrUrUrUrCrCrUrGrUrUrU; 
Rab7 siRNA2:
 Sense, 5′ rGrUrUrGrUrGrUrUrGrGrGrArArAr 
CrArArGrArUrUrGrACmC 
Antisense, 5′  rGrGrUrCrArArUrCrUrUrGrUr 
UrUrCrCrCrArArCrArCrArArCrArA; 
Rab7 siRNA3: 
Sense, 5′ rGrGrArArGrArArArGrUrGrUrUr 
GrCrUrGrArArGrGrUrCAT 
Antisense, 5′ rArUrGrArCrCrUrUrCrArGrCrAr 
ArCrArCrUrUrUrCrUrUrCrCrUrA)
Reactive oxygen species (ROS) measurement
Freshly isolated total bone marrow cells of wild type 
or lal–/– mice were transfected with control or Rab7 GTPase 
siRNAs for 3 days. The ROS level in CD11b+Ly6G+ cells 
was gated and measured by flow cytometry as previously 
described [10]. The ROS level in HD1A and HD1B cells 
was measured similarly. 
Mitochondrial membrane potential assay 
HD1A and HD1B cells were transfected with 
control or Rab7 GTPase siRNA in 24-well plate for 3 
d. The mitochondrial membrane potential was measure 
as described before [10]. For Ly6G+ bone marrow cells, 
freshly isolated whole bone marrow cells from wild 
type or lal–/– mice were transfected with control or Rab7 
GTPase siRNAs for 2 d, stained with the JC-1 (2 μM) and 
anti-Ly6G APCcy7 antibody (47-5931-82, eBiosciences), 
and analyzed for PE(red) and FITC(green) fluorescent 
cells in Ly6G+ gated cells by flow cytometry. 
Immunofluorescence staining
HD1A and HD1B cells were fixed for 15 min in 
4% paraformaldehyde, and permeabilized for 10 min in 
0.02% Triton X 100. After washing, cells were blocked 
with 5% normal goat serum in 1 x PBS for 1 h followed 
by incubation of primary rat anti-lysosomal associate 
membrane protein 1 (LAMP1) antibody (1:500) (sc1992, 
Santa Cruz, Dallas, TX), mouse anti-mTOR (1:500) 
(4517S, Cell Signaling), rabbit anti-mTOR (1:500) (2983, 
Cell Signaling), rabbit anti-Rab7 GTPase (1:500) (9367S, 
Cell Signaling) overnight. On the second day, cells were 
incubated with fluorescent conjugated secondary antibody 
for 1 h. Fluorescent images were examined under the 
Nikon fluorescence microscope.
Bone marrow-derived lineage negative (Lin-) cell 
differentiation in vitro
Bone marrow cells were isolated from wild type or 
lal–/– mice (8 to 10 weeks of age). A previously described 
procedure was used to isolate Lin- cells [33]. The cells 
were transfected with control or Rab7 GTPase siRNAs. 
Five days after in vitro culturing in RPMI1640 plus 10% 
FCS, CD11b+Ly6G+ cells derived from Lin- cells were 
gated and analyzed by flow cytometry.
Isolation of pulmonary endothelial cells (ECs) 
and Transwell assay 
ECs isolation and transwell assay were performed 
based on our published protocols [15]. 
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T cell proliferation in vitro
Proliferation of CD4+ T cells that were incubated 
with control or Rab7 GTPase siRNAs transfected bone 
marrow Ly6G+ cells was evaluated as carboxyfluorescein 
diacetate succinimidyl diester (CFSE, Molecular Probes) 
dilution peaks by flow cytometry [14]. 
Cancer cell growth in vitro and in vivo
Freshly isolated bone marrow Ly6G+ cells from the 
wild type or lal–/– mice were transfected with control or 
Rab7 GTPase siRNAs for 24 h, and 2 × 105 transfected 
Ly6G+ cells were co-cultured with B16 melanoma cells 
or LLC cells (2 × 104). After 48 h co-culture, unattached 
Ly6G+ cells were removed by washing, and the number of 
attached B16 melanoma cells or LLC cells was counted. 
Freshly isolated Ly6G+ cells from the C57BL/6 or 
FVB/N wild type or lal–/– bone marrow were transfected 
with control or Rab7 GTPase siRNAs for 24 h, and 6 ×  105 
of transfected Ly6G+ cells were mixed with 2 × 105 B16 
melanoma cells (3:1), or 15 × 105 of transfected Ly6G+ 
cells were mixed with 5 × 105 LLC cells (3:1) and 
incubated for 1 h, which were injected subcutaneously at 
left and right flank sites of wild type C57BL/6 or FVB/N 
recipient mice, respectively. The tumor size was measured 
10 d post-injection with calipers. The tumor volumes were 
determined using the formula: (length x width2) /2 [6]. At 
the end of the experiment, the animals were euthanized.  
Cancer cell invasion
Freshly isolated bone marrow Ly6G+ cells from 
C57BL/6 wild type or lal–/– mice were transfected with 
control or Rab7 GTPase siRNA for 24 h. Transfected 
Ly6G+ cells (2.5 × 106) were mixed with B16 melanoma 
cells (5 × 105) (5:1) and incubated for 1 h, which were 
intravenously injected into C57BL/6 wild type recipient 
mice through tail vein. For the B16 melanoma invasion, 
B16 melanoma colony numbers were counted at 2 weeks 
post injection. For LLC invasion, lung histology and Ki67 
immunohistochemical staining were examined at 2 months 
post injection.
Statistical analysis
A paired Student’s t-test or ANOVA was used to 
evaluate the significance of the differences. The results 
were mean ± SD of at least three independent experiments.
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